Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We've also had positive developments in our cases, challenging other agency actions of the FDA |
| And so we believe there is a significant opportunity both with neurologists and multiple sclerosis centers and consumers to be able to increase the awareness of the existence of this potentially quite useful product |
| We believe that this potential label expansion represents a significant opportunity for the Fanapt franchise given the high prevalence of bipolar disorder in the United States |
| So directly to your question, the increased specificity and quick reversibility both in amount and lymphocyte counts make this drug differentiated and attractive |
| We're pleased with our revenue performance despite the challenges of the at-risk launches of generic catalyst products |
| And we think our drug, PONVORY is well-positioned from the mechanism of vaccine with very key similarities to the receptor binding effects that both the BMS compound and the Pfizer compound we have, both of them successful in ulcerative colitis to give us reasons to believe that could be successful in that indication |
| Of course, we're optimistic because we believe in science and the robustness of our packages that we have already communicated with you all |
| And the BMS compound has been successfully addressing that as well as Pfizer's compound interestingly, not approved for multiple sclerosis do not pursue it, but actually directly being approved now for ulcerative colitis |
| On the Fanapt side, specifically, as Mihael mentioned, we have a very well-established commercial infrastructure given Fanapt's history on the market and as well as HETLIOZ's history on the market in the supporting activities and infrastructure associated with those |
| On the clinical side, as previously reported, in May of last year, we announced positive results from the first Phase III study of tradipitant in the treatment of motion sickness |
| So, I'd expect from a cadence perspective that there will be some preparation costs that we've began to execute against the first quarter, but more so, it would be upon a positive development that we would see a kind of cadence change |
| This acquisition represents a significant milestone for Vanda expanding our commercial portfolio, diversifying our sources of revenue and providing Vanda the opportunity to develop a potential therapeutic candidate for the treatment of a diverse group of inflammatory and autoimmune disorders ranging from psoriasis to ulcerative colitis |
| On Fanapt, for bipolar I disorder, as previously discussed in December of 2022, we announced positive results in our Phase III clinical study of Fanapt in acute manic and mixed episodes with bipolar I disorder in adults |
| Our HETLIOZ net product sales for the first quarter of 2023 reflected higher unit sales as compared to recent prior periods and has resulted in a significant increase of inventory stocking at specialty pharmacy customers throughout 2023 |
| Over the course of this year, we have taken a number of actions intended to position the commercial business for continued success, both with respect to existing products and indications as well as potential future products and indications |
| Our HETLIOZ net product sales as reported for the first quarter of 2023 reflected higher unit sales as compared to recent prior periods |
| Andrew Tsai Very good |
| In addition, Actelion, a J&J company, had conducted a Phase 2 large study in psoriasis, which was successful |
| And outside of this update on the tradipitant motion sickness program we’ll continue to progress our robust clinical development pipeline, which includes multiple products across a wide range of therapeutic areas |
| It has been clear that this drug may be attractive, especially to women of childbearing aids as they contemplate family planning and that the drug will come out of the circulation within a short period of time in a matter of days |
| Total revenues for the fourth quarter of 2023 increased by 17% as compared to $38.8 million in the third quarter of 2023 |
| HETLIOZ net product sales in the fourth quarter increased by 20% as compared to $17.5 million in the third quarter of 2023 |
| The FDA package supported by the results from clinic electrical studies 2301 and 3301, which we believe demonstrate substantial evidence of efficacy after tradipitant in this indication as well as a safety database to support the tolerability of this drug |
| That being said, we've certainly taken actions to be prepared to expand quickly on positive news |
| Fanapt net product sales in the fourth quarter of 2023 increased by 6% as compared to $21.3 million in the third quarter of 2023 |
| The higher unit sales during the first quarter of 2023 resulted in a significant increase of inventory stocking at specialty pharmacy customers throughout 2023 |
| And as I said, the opportunities around the once-day oral sphingosine-1-phosphate analog like PONVORY are just beginning to be realized and likely there will be wide |
| Thank you all for the developments |
| Mihael Polymeropoulos Thank you very much, Kevin and good afternoon everyone |
| Andrew Tsai Hey, good afternoon |
| Statement |
|---|
| For HETLIOZ in insomnia, of course, we think given the negative letter by the FDA of deficiencies, although not named, preclude label negotiations |
| HETLIOZ net product sales during the fourth quarter of 2023 reflect lower unit sales as compared to the fourth quarter of 2022, which was partially attributable to the continued reduction of the elevated inventory levels at specialty pharmacy customers from the end of the first quarter of 2023 |
| Fanapt prescriptions in the fourth quarter of 2023 as reported by IQVIA Xponent, decreased by approximately 3% compared to the third quarter of 2023 |
| Fanapt net product sales were $22.6 million for the fourth quarter of 2023, a 7% decrease compared to $24.4 million in the fourth quarter of 2022 |
| Fanapt net product sales of $90.9 million for the full year 2023 reflect a 4% decrease compared to $94.7 million for the same period in 2022 |
| HETLIOZ net product sales will likely decline in future periods potentially significantly related to the at-risk launch of generic versions of HETLIOZ in the US |
| HETLIOZ net product sales were $21.1 million for the fourth quarter of 2023, a 47% decrease compared to $40.1 million in the fourth quarter of 2022 |
| HETLIOZ net product sales were $100.2 million for the full year 2023 and saw a 37% decrease compared to $159.7 million for the same period in 2022 |
| Total revenues for the full year 2023 were $192.6 million, a 24% decrease compared to $254.4 million for the same period in 2022 |
| Total revenues for the fourth quarter of 2023 were $45.3 million, a 30% decrease compared to $64.5 million for the fourth quarter of 2022 |
| The decrease in net product sales relative to the fourth quarter of 2022 was attributable to a decrease in volume |
| The decrease to net product sales was attributable to a decrease in price net of deductions and a decrease in volume |
| Subsequent to that development on February 6, 2024, a Vanda filed suit in the US District Court for the District of Colombia, challenging the FDA's conduct in reviewing the insomnia sNDA |
| Given uncertainty surrounding the US market for HETLIOZ for the treatment of non-24 as a result of the ongoing HETLIOZ patent litigation and the at-risk launch of generic versions of HETLIOZ, Vanda is unable to provide 2024 financial guidance at this time |
| This suit alleges a pattern of FDA reviewers improperly disclosing proprietary information to generic companies as part of the review of generic versions of Fanapt and HETLIOZ |
| Vanda's cash, cash equivalents, and marketable securities referred to as cash as of December 31st, 2023, was $388.3 million representing a decrease of $101.6 million compared to cash as of September 30th, 2023, and a decrease of $78.6 million compared to December 31st, 2022 |
| Earlier this week, we announced that we had received a notification from the FDA stating that the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements and commitments at this time |
| As disclosed earlier this week, we received a notification from the FDA, stating that it had identified deficiencies that preclude discussion of labeling even though no deficiencies were identified |
| For the fourth quarter of 2023, Vanda recorded net loss of $2.4 million compared to net income of $6.9 million for the fourth quarter of 2022 and net income of $100,000 in the third quarter of 2023 |
| In September of 2022, we sued to compel the FDA to adhere to the procedural and timing requirements of the Food Drug Cosmetic Act with respect to our jet lag sNDA for HETLIOZ |
Please consider a small donation if you think this website provides you with relevant information